ExodusPoint Capital Management’s Mineralys Therapeutics MLYS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-101,052
Closed -$2.73M – 1996
2026
Q2
$2.73M Buy
+101,052
New +$2.77M 0.02% 700
2025
Q4
– Sell
-6,670
Closed -$253K – 1860
2025
Q3
$253K Sell
6,670
-165,882
-96% -$3.59M ﹤0.01% 1339
2025
Q2
$2.34M Buy
+172,552
New +$2.5M 0.02% 687
2024
Q3
– Sell
-274,316
Closed -$3.21M – 1904
2024
Q2
$3.21M Buy
274,316
+152,110
+124% +$1.92M 0.02% 598
2024
Q1
$1.58M Buy
122,206
+48,266
+65% +$596K 0.01% 798
2023
Q4
$636K Sell
73,940
-85,501
-54% -$671K ﹤0.01% 966
2023
Q3
$1.52M Sell
159,441
-34,084
-18% -$444K 0.01% 788
2023
Q2
$3.3M Buy
193,525
+12,213
+7% +$183K 0.03% 599
2023
Q1
$2.84M Buy
+181,312
New +$3.05M 0.02% 742

Other funds holding MLYS

ExodusPoint Capital Management's MLYS Position: Q3 2026 in Review

ExodusPoint Capital Management sold out of Mineralys Therapeutics (MLYS) in Q3 2026, closing a stake of 101,052 shares — an estimated $2.73M sold.

ExodusPoint Capital Management first reported a position in MLYS in Q1 2023 and held it in 9 quarters. The position peaked at $3.3M in Q2 2023. 163 funds tracked by Wall St. Rank hold MLYS as of Q3 2026.

  • ExodusPoint Capital Management reported no remaining Mineralys Therapeutics position as of Q3 2026 after selling out during the quarter.
  • ExodusPoint Capital Management sold 101,052 Mineralys Therapeutics shares in Q3 2026, an estimated $2.73M.
  • ExodusPoint Capital Management first reported a position in Mineralys Therapeutics in Q1 2023 and held it in 9 quarters.
  • ExodusPoint Capital Management's Mineralys Therapeutics position peaked at $3.3M in Q2 2023.
  • 163 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q3 2026.

Based on ExodusPoint Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.